Response at end of treatment with rituximab combined with liposomal doxorubicin in 17 patients with symptomatic KSHV-MCD
| NCI-KSHV-MCD Response Criteria . | ||
|---|---|---|
| Response category . | Response . | n(%) . |
| Clinical response | Complete response | 15 (88) |
| Symptom-free disease | 1 (6) | |
| Progressive disease§ | 1 (6) | |
| Major clinical response* | 16 (94) | |
| Biochemical response | Complete response | 13 (76) |
| Partial response | 2 (12) | |
| Major biochemical response† | 15 (88) | |
| Stable disease | 1 (6) | |
| Progressive disease§ | 1 (6) | |
| Radiographic response | Complete response | |
| Nodes | 13 (76) | |
| Spleen | 8 (47) | |
| Partial response | ||
| Nodes | 4 (24) | |
| Spleen | 7 (41) | |
| Major radiographic response‡ | 15 (88) | |
| Stable disease (spleen) | 1 (6) | |
| Progressive disease§ (spleen) | 1 (6) | |
| Overall response | Complete response | 5 (29) |
| Partial response | 9 (53) | |
| Stable disease | 2 (12) | |
| Progressive disease§ | 1 (6) | |
| KSHV-MCD Clinical Benefic Criteria | Complete response | 14 (82) |
| Partial response | 1 (6) | |
| Stable disease | 1 (6) | |
| Progressive disease | 1 (6) | |
| NCI-KSHV-MCD Response Criteria . | ||
|---|---|---|
| Response category . | Response . | n(%) . |
| Clinical response | Complete response | 15 (88) |
| Symptom-free disease | 1 (6) | |
| Progressive disease§ | 1 (6) | |
| Major clinical response* | 16 (94) | |
| Biochemical response | Complete response | 13 (76) |
| Partial response | 2 (12) | |
| Major biochemical response† | 15 (88) | |
| Stable disease | 1 (6) | |
| Progressive disease§ | 1 (6) | |
| Radiographic response | Complete response | |
| Nodes | 13 (76) | |
| Spleen | 8 (47) | |
| Partial response | ||
| Nodes | 4 (24) | |
| Spleen | 7 (41) | |
| Major radiographic response‡ | 15 (88) | |
| Stable disease (spleen) | 1 (6) | |
| Progressive disease§ (spleen) | 1 (6) | |
| Overall response | Complete response | 5 (29) |
| Partial response | 9 (53) | |
| Stable disease | 2 (12) | |
| Progressive disease§ | 1 (6) | |
| KSHV-MCD Clinical Benefic Criteria | Complete response | 14 (82) |
| Partial response | 1 (6) | |
| Stable disease | 1 (6) | |
| Progressive disease | 1 (6) | |
Major clinical response = complete response + symptom-free disease + partial response.
Major biochemical response = complete response + partial response.
Major radiographic response = at least complete response or partial response by both lymph nodes and spleen criteria.
One patient was not evaluable radiographically.